BTR Capital Management Inc. cut its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 9.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,650 shares of the medical research company’s stock after selling 175 shares during the quarter. BTR Capital Management Inc.’s holdings in Amgen were worth $321,000 at the end of the most recent reporting period.
Other institutional investors have also made changes to their positions in the company. Advisors Asset Management Inc. grew its stake in shares of Amgen by 1.0% during the 2nd quarter. Advisors Asset Management Inc. now owns 69,408 shares of the medical research company’s stock worth $12,812,000 after acquiring an additional 719 shares during the period. American National Bank grew its stake in shares of Amgen by 1.9% during the 3rd quarter. American National Bank now owns 26,849 shares of the medical research company’s stock worth $5,566,000 after acquiring an additional 504 shares during the period. Barometer Capital Management Inc. bought a new position in shares of Amgen during the 3rd quarter worth $13,204,000. Fox Run Management L.L.C. bought a new position in shares of Amgen during the 3rd quarter worth $312,000. Finally, Chemung Canal Trust Co. grew its stake in shares of Amgen by 3.4% during the 3rd quarter. Chemung Canal Trust Co. now owns 11,895 shares of the medical research company’s stock worth $2,466,000 after acquiring an additional 391 shares during the period. 76.90% of the stock is owned by hedge funds and other institutional investors.
In other Amgen news, SVP Cynthia M. Patton sold 1,777 shares of the firm’s stock in a transaction dated Thursday, November 29th. The stock was sold at an average price of $202.88, for a total value of $360,517.76. Following the completion of the transaction, the senior vice president now owns 23,090 shares in the company, valued at approximately $4,684,499.20. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website . Also, Director Tyler Jacks sold 20,000 shares of the firm’s stock in a transaction dated Thursday, December 6th. The stock was sold at an average price of $195.41, for a total value of $3,908,200.00. Following the completion of the transaction, the director now owns 28,979 shares of the company’s stock, valued at approximately $5,662,786.39. The disclosure for this sale can be found here . 0.27% of the stock is owned by company insiders.
AMGN has been the subject of several research reports. Citigroup increased their price target on Amgen from $204.00 to $210.00 and gave the stock a “neutral” rating in a research note on Friday, January 4th. Zacks Investment Research upgraded Amgen from a “hold” rating to a “buy” rating and set a $225.00 price target for the company in a research note on Monday, January 14th. Goldman Sachs Group reiterated a “buy” rating and set a $232.00 price target on shares of Amgen in a research note on Thursday, January 17th. Mizuho reiterated a “buy” rating and set a $206.00 price target on shares of Amgen in a research note on Friday, October 26th. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Amgen in a research note on Thursday, October 25th. One analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and nine have given a buy rating to the stock. Amgen has a consensus rating of “Hold” and an average price target of $203.98.
Shares of NASDAQ AMGN opened at $187.11 on Friday. Amgen, Inc. has a 52 week low of $163.31 and a 52 week high of $210.19. The company has a quick ratio of 2.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.05. The stock has a market capitalization of $122.42 billion, a price-to-earnings ratio of 12.99, a P/E/G ratio of 1.91 and a beta of 1.32.
Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, January 29th. The medical research company reported $3.42 EPS for the quarter, topping the consensus estimate of $3.26 by $0.16. Amgen had a return on equity of 63.99% and a net margin of 35.35%. The business had revenue of $6.23 billion during the quarter, compared to the consensus estimate of $5.88 billion. During the same quarter last year, the company earned $2.89 EPS. On average, equities analysts forecast that Amgen, Inc. will post 14.54 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Friday, March 8th. Shareholders of record on Friday, February 15th will be paid a $1.45 dividend. The ex-dividend date of this dividend is Thursday, February 14th. This represents a $5.80 annualized dividend and a yield of 3.10%. This is an increase from Amgen’s previous quarterly dividend of $1.32. Amgen’s dividend payout ratio (DPR) is currently 36.67%.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company’s products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.
Featured Story: How Do Tariffs Affect Trade Balances? Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN) Receive News & Ratings for Amgen Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Amgen and related companies with MarketBeat.com’s FREE daily email newsletter .
Click here to view original web page at BTR Capital Management Inc. Has $321,000 Position in Amgen, Inc. (AMGN)